GENE ONLINE|News &
Opinion
Blog

2021-09-29| In-DepthSpecial

Bispecific Antibodies or CAR T-Cells: Which One of These Cancer Immunotherapies Would Prevail?

by Rajaneesh K. Gopinath
Share To
A controversy session at the 2021 ESMO Annual Meeting focused on the debate where experts weighed on which among the two emerging cancer therapies—CAR T-cell therapy or bispecific antibodies would prevail in the long fight against cancer.

CAR-T therapy involves enhancing the cytotoxic ability of a patient's naïve T-cells by genetic manipulation. A foreign DNA is first introduced to produce the chimeric antigen receptor (CAR) on the T-cell surface, and the resulting CAR T-cells are expanded in vitro. They are then re-introduced to the patient, where they identify a specific cell surface antigen on cancer cells and attack them.

On the other hand, bispecific antibodies work by binding to two targets; one present on the cancer cell and another present on T cells. This way, a tumor cell and an activated immune cell are brought together to eradicate cancer.

GO Prime with only $1.49 now

LATEST
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
2022-07-05
Breakthrough Zebrafish Genome Database Now Available
2022-07-05
WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou
2022-07-05
Sanofi Launches Nonprofit Brand To Distribute Medicines to Low-Income Countries
2022-07-05
As Private Equity Sale Becomes Less Likely, Novartis May Gravitate Towards Sandoz Spinoff
2022-07-04
Ascletis Begins Study of PD-L1 Antibody Candidate Against HIV
2022-07-04
Akebia Therapeutics Gains $55M Following Deal Termination by Otsuka Pharmaceutical
2022-07-04
EVENT
2022-07-27
BIO Asia–Taiwan 2022
Online and on-side
2022-08-03
BIOPLUS-INTERPHEX KOREA
Seoul
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top